The search for an HIV cure: tackling latent infection.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Lancet. Infectious Diseases (Print)

• Publication date

  2013-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S1473-3099(13)70043-4PMID 23481675
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting HIV latency: pharmacologic strategies toward eradication.

  2013cited by this paper
• Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities

  2013cited by this paper
• Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells.

  2013cited by this paper
• Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog

  2013cited by this paper
• Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation.

  2013cited by this paper
• Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection

  2012cited by this paper
• Therapeutic vaccines against HIV infection

  2012cited by this paper
• Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV‐1 reservoirs: results from a multicentre randomized clinical study

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

  2012cited by this paper
• Combination of Biological Screening in a Cellular Model of Viral Latency and Virtual Screening Identifies Novel Compounds That Reactivate HIV-1

  2012cited by this paper
• Small molecules and big killers: the challenge of eliminating the latent HIV reservoir.

  2012cited by this paper
• HDAC inhibitors in HIV

  2012cited by this paper
• Therapeutic DNA Vaccine Induces Broad T Cell Responses in the Gut and Sustained Protection from Viral Rebound and AIDS in SIV-Infected Rhesus Macaques

  2012cited by this paper
• PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques.

  2012cited by this paper
• HIV reservoirs: pathogenesis and obstacles to viral eradication and cure

  2012cited by this paper
• Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards

  2012cited by this paper
• Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.

  2012cited by this paper
• Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4+ T cells from HIV-1-infected HAART-treated patients

  2012cited by this paper
• Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection

  2012cited by this paper
• Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• An “Escape Clock” for Estimating the Turnover of SIV DNA in Resting CD4+ T Cells

  2012cited by this paper
• Designed, Synthetically Accessible Bryostatin Analogues Potently Induce Activation of Latent HIV Reservoirs in vitro

  2012cited by this paper
• Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A

  2011cited by this paper
• Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir

  2011cited by this paper
• HIV latency.

  2011cited by this paper
• NK Cell Function and Antibodies Mediating ADCC in HIV-1-Infected Viremic and Controller Patients

  2011cited by this paper
• Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2.

  2011cited by this paper
• Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells

  2011cited by this paper
• A therapeutic dendritic cell-based vaccine for HIV-1 infection.

  2011cited by this paper
• Disulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4+ T Cell Model without Inducing Global T Cell Activation

  2011cited by this paper
• HIV: How to escape treatment

  2011cited by this paper
• Activation of NK Cells by ADCC Antibodies and HIV Disease Progression

  2011cited by this paper
• Profound early control of highly pathogenic SIV by an effector-memory T cell vaccine

  2011cited by this paper
• Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy.

  2011cited by this paper
• Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation.

  2011cited by this paper
• HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy

  2011cited by this paper
• Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial.

  2011cited by this paper
• HIV/AIDS and STD Updates

  2011cited by this paper
• Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine

  2011cited by this paper
• Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo

  2010cited by this paper
• Compromised gastrointestinal integrity in pigtail macaques is associated with increased microbial translocation, immune activation and IL-17 production in the absence of SIV infection

  2010cited by this paper
• Profound Depletion of HIV-1 Transcription in Patients Initiating Antiretroviral Therapy during Acute Infection

  2010cited by this paper
• Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection

  2010cited by this paper
• CD56 negative NK cells: origin, function, and role in chronic viral disease.

  2010cited by this paper
• A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model.

  2010cited by this paper
• Evidence for the cure of HIV infection by CCR 5 { Delta } 32 / { Delta } 32 stem cell transplantation

  2010cited by this paper
• Cell line-dependent variability in HIV activation employing DNMT inhibitors

  2010cited by this paper
• HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

  2010cited by this paper
• No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy.

  2010cited by this paper
• The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells

  2009cited by this paper
• HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

  2009cited by this paper
• Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

  2009cited by this paper
• Interleukin-2 therapy in patients with HIV infection.

  2009cited by this paper
• Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.

  2009cited by this paper
• Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells.

  2009cited by this paper
• The Challenge of Finding a Cure for HIV Infection

  2009cited by this paper
• Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir

  2008cited by this paper
• Closed Chromatin Architecture Is Induced by an RNA Duplex Targeting the HIV-1 Promoter Region

  2008cited by this paper
• The utility of ADCC responses in HIV infection.

  2008cited by this paper
• Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases

  2008cited by this paper
• Control of Viremia and Prevention of AIDS following Immunotherapy of SIV-Infected Macaques with Peptide-Pulsed Blood

  2008cited by this paper
• Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States.

  2007cited by this paper
• Upregulation of PD-1 Expression on HIV-Specific CD8+ T Cells Leads to Reversible Immune Dysfunction

  2007cited by this paper
• Influence of IFNγ Co-Expression on the Safety and Antiviral Efficacy of Recombinant Fowlpox Virus HIV Therapeutic Vaccines Following Interruption of Antiretroviral Therapy

  2007cited by this paper
• Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy.

  2007cited by this paper
• Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.

  2007cited by this paper
• PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

  2006cited by this paper
• Therapeutic immunization in HIV infection

  2006cited by this paper
• Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction

  2006cited by this paper
• Depletion of Latent HIV-1 Infection In Vivo: A Proof-of-Concept Study

  2006cited by this paper
• CD4+ count-guided interruption of antiretroviral treatment.

  2006cited by this paper
• The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure

  2006cited by this paper
• Corrigendum: Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction

  2006cited by this paper
• AIDS Res Hum Retroviruses

  2006cited by this paper
• Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.

  2005cited by this paper
• IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.

  2005cited by this paper
• Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection.

  2005cited by this paper
• Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094).

  2005cited by this paper
• Evaluating therapeutic vaccines in patients infected with HIV

  2004cited by this paper
• HIV and SIV CTL escape: implications for vaccine design

  2004cited by this paper
• The impaired NK cell cytolytic function in viremic HIV‐1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44)

  2003cited by this paper
• Natural killer cells in HIV-1 infection: Dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates

  2003cited by this paper
• Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence

  2003cited by this paper
• Modelling viral and immune system dynamics

  2002cited by this paper
• Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial)

  2002cited by this paper
• Compartmentalization of Surface Envelope Glycoprotein of Human Immunodeficiency Virus Type 1 during Acute and Chronic Infection

  2002cited by this paper
• Virus Dynamics: Mathematical Principles of Immunology and Virology

  2001cited by this paper
• Antibody from Patients with Acute Human Immunodeficiency Virus (HIV) Infection Inhibits Primary Strains of HIV Type 1 in the Presence of Natural-Killer Effector Cells

  2001cited by this paper
• Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy

  1999cited by this paper
• Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

  1999cited by this paper
• Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy.

  1999cited by this paper
• Expression of ζ molecules is decreased in NK cells from HIV-infected patients

  1999cited by this paper
• Expression of zeta molecules is decreased in NK cells from HIV-infected patients.

  1999cited by this paper
• Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

  1997cited by this paper
• Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

  1997cited by this paper
• Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

  1997cited by this paper
• Clinical Progression of HIV Infection: Role of NK Cells

  1997cited by this paper
• Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity.

  1995cited by this paper

• Intact HIV DNA decays in children with and without complete viral load suppression

  2025cites this paper
• Herbal formulations, Product Nkabinde and Gnidia sericocephala, exhibit potent in vitro activity against HIV-1 infection

  2025cites this paper
• Tat-dependent Conditionally Replicating Adenoviruses Expressing Diphtheria Toxin A for Specifically Killing HIV-1 Infected Cells.

  2024cites this paper
• Optimal Perturbations of Systems with Delayed Independent Variables for Control of Dynamics of Infectious Diseases Based on Multicomponent Actions

  2021cites this paper
• Negative diagnostic PCR tests in school-aged, HIV-infected children on antiretroviral therapy since early life in Johannesburg, South Africa.

  2020cites this paper
• Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial

  2019cites this paper
• Revisiting the ‘sterilising cure’ terminology: a call for more patient-centred perspectives on HIV cure-related research

  2019cites this paper
• Between a shock and a hard place: challenges and developments in HIV latency reversal.

  2019cites this paper
• A defucosylated bispecific multivalent molecule exhibits broad HIV-1-neutralizing activity and enhanced antibody-dependent cellular cytotoxicity against reactivated HIV-1 latently infected cells

  2018cites this paper
• Contrasting effect of the latency-reversing agents bryostatin-1 and JQ1 on astrocyte-mediated neuroinflammation and brain neutrophil invasion

  2017cites this paper
• Maximum response perturbation-based control of virus infection model with time-delays

  2017cites this paper
• Impact of Allogeneic Hematopoietic Stem Cell Transplantation on the HIV Reservoir and Immune Response in 3 HIV-Infected Individuals

  2017cites this paper
• Male circumcision to prevent syphilis in 1855 and HIV in 1986 is supported by the accumulated scientific evidence to 2015: Response to Darby

  2017cites this paper
• Control of models of virus infections with delayed variables, based on optimal disturbances

  2017cites this paper
• Mathematical modelling of blood coagulation and thrombus formation under flow in normal and pathological conditions

  2017cites this paper
• Mechanisms of HIV persistence in HIV reservoirs

  2017cites this paper
• Wake me up before you go: a strategy to reduce the latent HIV reservoir.

  2017cites this paper
• Towards a Multiscale Model of Acute HIV Infection

  2017cites this paper
• Molecular Modeling Applied to Nanobiosystems

  2017cites this paper
• Latency reversing agents affect HIV RNA splicing

  2017cites this paper
• 105 – Eradication and Cure of HIV

  2017cites this paper
• Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDS

  2016cites this paper
• NKG2D Acts as a Co-Receptor for Natural Killer Cell-Mediated Anti-HIV-1 Antibody-Dependent Cellular Cytotoxicity

  2016cites this paper
• The role of HIV integration in viral persistence: no more whistling past the proviral graveyard.

  2016cites this paper
• Ending the HIV/AIDS epidemic in low- and middle-income countries by 2030: is it possible?

  2016cites this paper
• Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells

  2016cites this paper
• Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research

  2016cites this paper
• An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.

  2016cites this paper
• Stochastic modelling of the eradication of the HIV-1 infection by stimulation of latently infected cells in patients under highly active anti-retroviral therapy

  2016cites this paper
• The potential role for romidepsin as a component in early HIV-1 curative efforts

  2016cites this paper
• Curing HIV: Moving Forward Faster

  2016cites this paper
• Promoter Targeting RNAs: Unexpected Contributors to the Control of HIV-1 Transcription

  2015cites this paper
• Inhibition of HIV-1 infection of primary CD 4 + T-cells by gene editing of CCR 5 using adenovirus-delivered CRISPR / Cas 9

  2015cites this paper
• Antibody-dependent effector functions against HIV decline in subjects receiving antiretroviral therapy.

  2015cites this paper
• TWO DISEASES (TB/HIV) AND TWO MEDICINES (ATT/ART): ONE PATIENT AND ONE SERVICE!

  2015cites this paper
• Nanoformulation of antiretroviral drugs enhances their penetration across the blood brain barrier in mice.

  2015cites this paper
• Is HIV post‐exposure prophylaxis required following occupational exposure to a source patient who is virologically suppressed on antiretroviral therapy?

  2015cites this paper
• Towards a scalable HIV cure research agenda: the role of co-infections

  2015cites this paper
• Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.

  2015cites this paper
• C URRENT OPINION Advancing the HIV cure agenda: the next 5 years

  2015cites this paper
• OPINION Advancing the HIV cure agenda: the next 5 years

  2015cites this paper
• Advancing the HIV cure agenda: the next 5 years

  2015cites this paper
• Progress and challenges in the use of latent HIV-1 reactivating agents

  2015cites this paper
• The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.

  2015cites this paper
• Apoptosis-induced activation of HIV-1 in latently infected cell lines

  2015cites this paper
• Phenotypical and functional profiles of natural killer cells exhibiting matrix metalloproteinase‐mediated CD16 cleavage after anti‐HIV antibody‐dependent activation

  2015cites this paper
• Bioinformatics and HIV Latency

  2015cites this paper
• HIV-1 transcriptional regulation in the central nervous system and implications for HIV cure research

  2014cites this paper
• Modeling the Timing of Antilatency Drug Administration during HIV Treatment

  2014cites this paper
• identifies issues in the medical literature of interest to clinicians in Africa

  2014cites this paper
• The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies?

  2014cites this paper
• One Step Closer to HIV Eradication?

  2014cites this paper
• Administration during HIV Treatment Modeling the Timing of Antilatency Drug

  2014cites this paper
• Modulating Autophagy to Cure Human Immunodeficiency Virus type‐1

  2014cites this paper
• Tentative fi rst steps to eradicate latent HIV

  2014cites this paper
• [Pediatric HIV infections in developed countries: current situation and future challenges].

  2014cites this paper
• One Step Closer to HIV

  2014cites this paper
• Anti-HIV Antibody–Dependent Activation of NK Cells Impairs NKp46 Expression

  2014cites this paper
• Stochastic modelling of cellular populations: Effects of latency and feedback

  2014cites this paper
• Infection de l’enfant par le VIH dans les pays industrialisés - État des lieux et enjeux futurs

  2014cites this paper
• Tentative first steps to eradicate latent HIV.

  2014cites this paper
• Measuring Turnover of SIV DNA in Resting CD4+ T Cells Using Pyrosequencing: Implications for the Timing of HIV Eradication Therapies

  2014cites this paper
• Intracellular Dynamics of HIV Infection

  2013cites this paper
• [Joint collaboration in infectious diseases in China, the University of Tokyo].

  2013cites this paper
• Obstacles to ideal anti-HIV antibody-dependent cellular cytotoxicity responses.

  2013cites this paper
• Baby steps on the road to HIV eradication.

  2013cites this paper
• bstacles to ideal anti-HIV antibody-dependent cellular cytotoxicity

  2013cites this paper
• Bromodomain Proteins in HIV Infection

  2013cites this paper
• Quantifying the Turnover of Transcriptional Subclasses of HIV-1-Infected Cells

  2013cites this paper
• Eradication of HIV and Cure of AIDS, Now and How?

  2013cites this paper